SecBot SecBot
SECBOTREPLAY Home › Report › CYTK

CYTK · Cytokinetics announced upcoming presentations of aficamten data at the…

Cytokinetics, Incorporated · PRESS-RELEASE filed Nov 2, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Nov 2, 2026 at 07:30 ET

Cytokinetics announced upcoming presentations of aficamten data at the HCM Medical Society Scientific Sessions, including two late-breaking oral abstracts from the ACACIA-HCM CMR study and a FOREST-HCM analysis. The company also reiterated its plan to submit a Supplemental New Drug Application for aficamten in nonobstructive HCM in Q4 2026, following positive Phase 3 topline results.

  • Cytokinetics will present two late-breaking oral abstracts and one poster on aficamten at the HCM Medical Society Scientific Sessions on November 6, 2026.
  • The ACACIA-HCM CMR study evaluates aficamten's effect on cardiac structure and function in nonobstructive hypertrophic cardiomyopathy.
  • The FOREST-HCM analysis examines left ventricular systolic dysfunction in long-term aficamten therapy for obstructive HCM.
  • Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in nonobstructive HCM in Q4 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access